# A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions

> **NCT07421375** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 58 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** BR1015-A
- **DRUG:** BR1015-1
- **DRUG:** BR1015-2

## Key facts

- **NCT ID:** NCT07421375
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-02
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07421375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07421375, "A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-1 and BR1015-2 Under Fasting Conditions". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07421375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*